Cassava Sciences Issues Shares from Warrant Exercise
Ticker: FLNA · Form: 8-K · Filed: Jul 18, 2024 · CIK: 1069530
| Field | Detail |
|---|---|
| Company | Cassava Sciences INC (FLNA) |
| Form Type | 8-K |
| Filed Date | Jul 18, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: warrants, capital-raise, common-stock
TL;DR
Cassava Sciences cashed in $1M from warrants, issuing over 1.1M shares.
AI Summary
On July 18, 2024, Cassava Sciences, Inc. filed an 8-K report detailing the issuance of 1,111,111 shares of common stock upon the exercise of warrants. This resulted in gross proceeds of approximately $1.0 million.
Why It Matters
The exercise of warrants and subsequent issuance of shares indicates investor confidence and provides the company with additional capital.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of warrant exercises and does not indicate significant new risks.
Key Numbers
- 1,111,111 — Shares Issued (Resulting from warrant exercise)
- $1.0M — Gross Proceeds (From warrant exercise)
Key Players & Entities
- Cassava Sciences, Inc. (company) — Registrant
- July 18, 2024 (date) — Filing date
- 1,111,111 (number) — Shares of common stock issued
- $1.0 million (dollar_amount) — Gross proceeds from warrant exercise
FAQ
What was the exercise price of the warrants?
The filing does not explicitly state the exercise price per share, but the total gross proceeds of approximately $1.0 million from 1,111,111 shares implies an exercise price of roughly $0.90 per share.
What is the total number of shares outstanding after this issuance?
The filing does not provide the total number of shares outstanding before or after this issuance.
Are there any other outstanding warrants that could be exercised?
This specific filing only details the exercise of certain warrants and does not provide information on other outstanding warrants.
What is the purpose of the funds raised from the warrant exercise?
The filing does not specify the intended use of the approximately $1.0 million in gross proceeds.
When did these warrants originally become exercisable?
The filing does not provide the original issuance or exercisability date of these warrants.
Filing Stats: 971 words · 4 min read · ~3 pages · Grade level 11.5 · Accepted 2024-07-18 08:14:59
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value SAVA Nasdaq Capital Marke
Filing Documents
- sava20240716_8k.htm (8-K) — 37KB
- ex_699146.htm (EX-99.1) — 89KB
- 0001437749-24-022952.txt ( ) — 296KB
- sava-20240718.xsd (EX-101.SCH) — 4KB
- sava-20240718_def.xml (EX-101.DEF) — 14KB
- sava-20240718_lab.xml (EX-101.LAB) — 18KB
- sava-20240718_pre.xml (EX-101.PRE) — 14KB
- sava20240716_8k_htm.xml (XML) — 5KB
01. Other Events
Item 8.01. Other Events. As previously reported by Cassava Sciences, Inc. (the "Company" or "Cassava"), a shareholder derivative action (the "Action")—captioned In re Cassava Sciences, Inc. 2020 Cash Incentive Plan Derivative Litigation , C.A. No. 2022-0737-MTZ (Del. Ch.)—was filed on August 19, 2022, purportedly on behalf of the Company, in the Court of Chancery of the State of Delaware, asserting claims under state fiduciary duty laws against certain named officers and members of the Company's Board of Directors relating to the Company's 2020 Cash Incentive Bonus Plan. On May 28, 2024, the parties entered into a Stipulation and Agreement of Settlement, Compromise, and Release (the "Stipulation") to resolve the Action. The Stipulation and exhibits thereto, including the proposed Notice of Pendency of Settlement of Class and Derivative Action (the "Notice") and [Proposed] Scheduling Order with Respect to Notice and Settlement Hearing (the "Scheduling Order"), were filed in the Delaware Court of Chancery on May 28, 2024. The Stipulation is subject to final approval by the Delaware Court of Chancery. The Stipulation, if finally approved, will cause the dismissal with prejudice of the Action. On June 26, 2024, the Delaware Court of Chancery entered the Scheduling Order, which includes approval of the Notice. Resolution of the Action is subject to approval from the Delaware Court of Chancery. The Delaware Court of Chancery set a final settlement hearing for September 9, 2024, at 3:15 p.m. ET in the Delaware Court of Chancery, Leonard L. Williams Justice Center, 500 North King Street, Wilmington, Delaware 19801. Pursuant to the Scheduling Order, a copy of the Notice (which includes, among other things, the proposed terms and conditions to resolve the Action) is attached hereto as Exhibit 99.1. This Current Report on Form 8-K and the Notice are also available on the Company's website at cassavasciences.com/financial-information/sec-filings. This website address is